The incidence of malignant tumors in SARA+/Δ mice was similar or slightly increased: 12.1% of SARA+/Δ tumors exhibited well-differentiated SCCs and 6.1% showed moderately-differentiated SCCs (Figure 8B and C). Here, ZFYVE9 is linked to cancer.